Abstract
The anticonvulsant and neuroprotective properties of agonist and antagonist of metabotropic glutamate receptors (mGluRs ) have been known for 15 years or so. However, it is not yet clear whether these agents, and allied compounds, can be considered as candidate drugs for eventual use in the clinic to control the development of epilepsy, (i.e. as anti- epileptogenics), or for the control of seizures themselves (i.e. as anticonvulsants). In fact, few studies have been designed to test for these properties by, for instance, administering these agents during the chronic stages of experimental epilepsy to determine whether a tendency to generate spontaneously recurrent seizures, which often appear by epileptogenesis, could be prevented or stopped. Even in the acute stages, there are substantial differences in experimental design between the published studies. Thus, there are large variations in such factors as timing, and the route of administration of candidate drugs, the age, or species and strain of experimental animal used, and the experimental epilepsy model employed. Such variations often make it difficult to accurately assess the anticonvulsant, neuroprotective and antiepileptogenic properties of each candidate drug across a wide range of studies. This paper, will review neuroanatomical, neurochemical, neuropharmacological studies of mGluRs in animal models and in patients with temporal lobe epilepsy, and summarize anticonvulsive and neuroprotective effects of their agonists and antagonists in different seizure and epilepsy models in order to give direction for the development of new generation antiepileptogenic and anticonvulsive drugs.
Keywords: Metabotropic glutamate receptors (mGluRs), agonists and antagonists, anticonvulsive, anti-epileptogenic, glutamate- induced epileptic discharges
Current Medicinal Chemistry
Title: Metabotropic Glutamate Receptors in the Control of Neuronal Activity and as Targets for Development of Anti-Epileptogenic Drugs
Volume: 16 Issue: 17
Author(s): Feng Ru Tang, Henry F. Bradford and Eng-Ang Ling
Affiliation:
Keywords: Metabotropic glutamate receptors (mGluRs), agonists and antagonists, anticonvulsive, anti-epileptogenic, glutamate- induced epileptic discharges
Abstract: The anticonvulsant and neuroprotective properties of agonist and antagonist of metabotropic glutamate receptors (mGluRs ) have been known for 15 years or so. However, it is not yet clear whether these agents, and allied compounds, can be considered as candidate drugs for eventual use in the clinic to control the development of epilepsy, (i.e. as anti- epileptogenics), or for the control of seizures themselves (i.e. as anticonvulsants). In fact, few studies have been designed to test for these properties by, for instance, administering these agents during the chronic stages of experimental epilepsy to determine whether a tendency to generate spontaneously recurrent seizures, which often appear by epileptogenesis, could be prevented or stopped. Even in the acute stages, there are substantial differences in experimental design between the published studies. Thus, there are large variations in such factors as timing, and the route of administration of candidate drugs, the age, or species and strain of experimental animal used, and the experimental epilepsy model employed. Such variations often make it difficult to accurately assess the anticonvulsant, neuroprotective and antiepileptogenic properties of each candidate drug across a wide range of studies. This paper, will review neuroanatomical, neurochemical, neuropharmacological studies of mGluRs in animal models and in patients with temporal lobe epilepsy, and summarize anticonvulsive and neuroprotective effects of their agonists and antagonists in different seizure and epilepsy models in order to give direction for the development of new generation antiepileptogenic and anticonvulsive drugs.
Export Options
About this article
Cite this article as:
Tang Ru Feng, Bradford F. Henry and Ling Eng-Ang, Metabotropic Glutamate Receptors in the Control of Neuronal Activity and as Targets for Development of Anti-Epileptogenic Drugs, Current Medicinal Chemistry 2009; 16 (17) . https://dx.doi.org/10.2174/092986709788612710
DOI https://dx.doi.org/10.2174/092986709788612710 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Protein Tyrosine Phosphatases in Plants
Current Genomics Convection Enhanced Delivery of Macromolecules for Brain Tumors
Current Drug Discovery Technologies Astrocyte-Microglia Cooperation in the Expression of a Pro-Inflammatory Phenotype
CNS & Neurological Disorders - Drug Targets Diabetes, Cognitive Function, and the Blood-Brain Barrier
Current Pharmaceutical Design Old and New Antiepileptic Drugs for the Treatment of Idiopathic Generalized Epilepsies
Current Clinical Pharmacology New Hopes in Cancer Battle - A Review of New Molecules and Treatment Strategies
Medicinal Chemistry Pharmacological Innovations for Posttraumatic Stress Disorder and Medication- Enhanced Psychotherapy
Current Pharmaceutical Design Patient-Specific Induced Pluripotent Stem Cell Models in Mitochondrial Diseases
Current Stem Cell Research & Therapy 3D-QSAR and Docking Simulation Studies of Some Benzopyrone Derivatives as Inhibitors for Breast Cancer Stem Cell Growth via PGlycoprotein Mediated Efflux
Current Bioinformatics Neuronal Nicotinic Acetylcholine Receptors - Targets for the Development of Drugs to Treat Cognitive Impairment Associated with Schizophrenia and Alzheimers Disease
Current Topics in Medicinal Chemistry Relationship Between Susceptibility to DMCM-Induced Generalized Motor Convulsions and Low-Affinity [3H]-Ouabain Binding in Membranes in Rat Brain
Current Molecular Pharmacology Symptomatic Treatment of Chronic Neuropathic Pain with Gabapentin Clinical Practice and Research Prospective
Current Neuropharmacology n-3 Fatty Acids: Role in Neurogenesis and Neuroplasticity
Current Medicinal Chemistry Molecular Targets of Cannabinoids Associated with Depression
Current Medicinal Chemistry Heterocyclic Compounds as Anti-Inflammatory Agents
Current Bioactive Compounds Amantadine, Apomorphine and Zolpidem in the Treatment of Disorders of Consciousness
Current Pharmaceutical Design Investigation of the Roles of New Antiepileptic Drugs and Serum BDNF Levels in Efficacy and Safety Monitoring and Quality of Life: A Clinical Research
Current Clinical Pharmacology Editorial (Thematic Issue: Measurements of ABC Transporters at the Blood-Brain Barrier: Novel Methods and Applications)
Current Pharmaceutical Design Editorial (Thematic Issue: Global Trends for Nanotechnological Approaches in Various Health Issues - Part 1)
Current Drug Metabolism Obstructive Sleep Apnea Syndrome: From Phenotype to Genetic Basis
Current Genomics